Jason Bishai's research while affiliated with Broad Institute of MIT and Harvard and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
Inflammatory bowel diseases (IBD) are associated with alterations in gut microbial abundances and lumenal metabolite concentrations, but the effects of specific metabolites on the gut microbiota in health and disease remain largely unknown. Here, we analysed the influences of metabolites that are differentially abundant in IBD on the growth and phy...
Background:
Alterations in the microbiome have been postulated to drive inflammation in IBD. In this pilot randomized controlled trial, we evaluated the effectiveness of quadruple antibiotic cocktail in addition to intravenous-corticosteroids (IVCSs) in acute severe colitis (ASC).
Methods:
Hospitalized children with ASC (pediatric ulcerative col...
Background
Acute severe ulcerative colitis (ASC) is one of the few medical emergencies of gastroenterology. We previously reported the clinical results of the PRASCO randomised controlled trial in which oral antibiotics (AB) improved disease activity after 5 days of treatment in children with ASC. This suggests that the microbiome is implicated in...
Background
A previous case series suggested a benefit of antibiotic-cocktail in steroid-refractory paediatric UC. In this pilot randomised investigator-blinded controlled trial we aimed to evaluate the effectiveness of wide-spectrum antibiotic regimens in acute severe colitis (ASC) in addition to standard intravenous corticosteroid (IVCS) therapy....
Citations
... These commensal bacteria utilize host lipids as an energy source and metabolize some lipids to new isoforms to enhance mucosal barrier function. Conversely, gut bacteria have also been associated with detrimental changes to dietary lipids, as demonstrated by studies of the microbiome associated with irritable bowel syndrome (69,70). These studies begin to shed light on the potential circular relationship between dietary lipids, changes in the local host environment, and selection for bacteria that metabolize those same nutrients and benefit from changes to the environment (71). ...
... Secondary endpoints such as remission rate and calprotectin levels were numerically better in the intervention group but did not reach statistical significance in this small study. 142 Although this study only involved patients with ulcerative colitis, the Jerusalem cocktail is already being used in IBD situations, where previous studies have shown the benefit of antibiotics such as vancomycin, metronidazole, and ciprofloxacin. ...
... [56][57][58][59][60] Antibiotics have been tried in small cohorts of VEO-IBD with UC. Turner et al report some promising results including some very early onset UC patients receiving metronidazole, amoxicillin, doxycycline +/-vancomycin 61,62 and results also on use of oral gentamycin and/or vancomycin for treating VEO-IBD. 63 When there is a monogenic cause, identifying the underlying genetic etiology can enable more targeted and successful therapeutic interventions and/or help avoid ones that would be especially harmful to a patient. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/600909453209606-1520279386846_Q64/Moran-Yassour.jpg)
